Seres Therapeutics to Present at H.C. Wainwright Conference
Event summary
- Seres Therapeutics will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026, at 2 p.m. ET.
- The company is developing SER-155, a Phase 2-ready biotherapeutic with Breakthrough Therapy and Fast Track designations.
- SER-155 is being evaluated for preventing bloodstream infections in stem cell transplant patients and treating immune checkpoint inhibitor-related enterocolitis.
- Seres is advancing IND-enabling studies for SER-603, targeting inflammatory bowel disease.
The big picture
Seres Therapeutics is positioning itself as a leader in live biotherapeutics, targeting critical unmet needs in oncology and inflammatory diseases. The company's focus on modulating the mucosal epithelial barrier-immune interface aligns with broader industry trends toward precision medicine and immune modulation. The upcoming conference presentation provides an opportunity to gauge investor interest and strategic partnerships in this evolving sector.
What we're watching
- Clinical Progress
- The pace at which SER-155 advances through Phase 2 trials will determine its commercial viability.
- Funding Dynamics
- Whether Seres can secure the necessary funding to move SER-155 forward remains a key uncertainty.
- Market Positioning
- How Seres differentiates itself in the competitive landscape of microbiome therapeutics.
Related topics